Silver Book Fact

After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.

Patel J, Chen F, Da Cruz L, Rubin G, et al. Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf

Reference

Title
Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
February 2011
Authors
Patel J, Chen F, Da Cruz L, Rubin G, et al.
Volume & Issue
Volume 52, Issue 6
Pages
3089-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…